Clinical Trials Logo

Clinical Trial Summary

Vaccines routinely used are extremely safe; however, severe adverse events to vaccines do occur. As vaccination against COVID-19 has begun, adverse events to the vaccine, particularly Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis, after COVID-19 vaccination have been reported worldwide. Study hypothesis: there are genetic factors that contribute to increased risks of particular COVID-19 vaccine-induced adverse events. The objective of the study is to determine if there are specific genetic factors strongly associated with each of the COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis).


Clinical Trial Description

Purpose: Reduce the risk of COVID-19 vaccine-induced adverse events (i.e., GBS, VITT/TTS, and myocarditis/pericarditis) through improved understanding of the biology underlying these severe adverse events and the genetic contribution to their cause Research Design: - Prospective case-control study designs will be performed to investigate the genetic associations of Guillain-Barré syndrome (GBS), vaccine-induced immune thrombotic thrombocytopenia (VITT)/thrombosis with thrombocytopenia syndrome (TTS), and myocarditis/pericarditis strongly associated (OR ≥ 3.0) with COVID-19 vaccination. - Determined cases of specific COVID-19 vaccine-induced GBS, VITT/TTS, and myocarditis/pericarditis, and vaccinated controls without these adverse events will be included. - Saliva DNA samples from eligible adverse event cases and vaccinated controls will be collected. - Candidate gene and genome-wide association studies (GWAS) approaches will be conducted. - Genomics analyses will be stratified by severity, age, sex, vaccine, and other critical covariates as determined by the GVDN Work Group for each adverse event and as adequately powered analyses allow. - To complement GWAS, particularly in protein-coding regions, additional whole-exome sequencing (WES) will be performed on the most severe patients who are categorized as Brighton Collaboration Level One case of COVID-19 vaccine-induced adverse events to identify the most possible disease-causing mutations. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05212792
Study type Observational
Source University of British Columbia
Contact Bruce Carleton, PharmD
Phone 1.877.878.4131
Email [email protected]
Status Recruiting
Phase
Start date June 24, 2022
Completion date December 2025

See also
  Status Clinical Trial Phase
Completed NCT04530357 - Reactogenicity, Safety and Immunogenicity of QazCovid-in® COVID-19 Vaccine Phase 1/Phase 2
Terminated NCT03966300 - Improving the School Vaccination Experience: What CARDs Are You Going to Play? N/A
Active, not recruiting NCT05483725 - Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
Not yet recruiting NCT05546502 - Safety and Immunogenicity of SARS-CoV-2 Protein Subunit Recombinant Vaccine in Healthy Children Phase 2/Phase 3
Not yet recruiting NCT05482295 - Immunogenicity and Safety Following In-House Recombinant Hepatitis B Vaccine in Indonesian Population (Phase III) Phase 3
Completed NCT03600428 - Safety of LAIV4 in Children With Asthma Phase 4
Completed NCT03400878 - Comparing Morbidity and Mortality Effects of Two Different Strains of BCG Phase 4
Recruiting NCT05116748 - COVID19 Vaccine in SOT Adult Recipients
Recruiting NCT05128721 - Evaluation of Inactivated Vaccine in Healthy Adults Against Coronavirus Disease of 2019 (COVID-19) Phase 1
Recruiting NCT04894682 - Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor
Not yet recruiting NCT05387252 - Glucoside- and Rutinoside-rich Crude Material for Relieving Side Effects of COVID-19 Vaccines N/A
Suspended NCT03966391 - Effectiveness of CARD for Improving School-Based Immunizations N/A
Active, not recruiting NCT04801667 - Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients Phase 4
Not yet recruiting NCT05283902 - Effectiveness, Immunogenicity and Safety of the Second Booster Dose of the Vaccine Against COVID-19 in the Elderly
Recruiting NCT05095844 - National Vaccine Adverse Event Reporting Survey and Etiology
Recruiting NCT05315856 - Reactogenicity, Immunogenicity and Inflammatory Response by New COVID-19 Vaccine Platforms
Recruiting NCT05258708 - COVID-19 Vaccine Reactogenicity and Immunogenicity
Not yet recruiting NCT05409261 - Evaluation of the Immunogenicity and Safety of COVID-19 Vaccines (Ad26.COV2.S and NVX-CoV2373) Phase 2
Active, not recruiting NCT04930003 - Reactogenicity, Safety and Immunogenicity of QazCoVac-P COVID-19 Vaccine Phase 1/Phase 2
Completed NCT04923386 - mRNA Based-Covid-19 Vaccine Effects on Blood Glucose Levels